Catalyst Wire Dossier Catalyst Wire Dossier

PF-06410293

adalimumab · Pfizer
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for PF-06410293, covering 2014-02-14 to 2022-08-22. Get the full timeline:

Most recent: Clinical Trial Update: A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis [Phase 3]

See pricing